The real-life management of glucose homeostasis abnormalities in pediatric onco-hematological diseases: data from a national survey
Angela ZanfardinoPatrizia BruzziMichela TradaNovella RapiniEmanuela LaudaniGianluca TorneseFederica OrtolaniGianluca PiccoloLorena MatontiMaria Alessandra SaltarelliTiziana TimpanaroGiuseppe D'AnnunzioBarbara PredieriFrancesca RossiRossella MuraVeronica BaratArcangelo PreteRiccardo SchiaffiniStefano Zucchinia University of the Study of Campania,Naples,Italyb Paediatric Unit,Department of Medical and Surgical Sciences of Mothers,Children and Adults,University of Modena & Reggio Emilia,Modena,Italyc Center of Pediatric Diabetology-A.O.U. Città della Salute e della Scienza di Torino,Turin,Italyd Diabetology and Growth Disorders Unit,Bambino Gesù Children's Hospital,IRCCS,Rome,Italye Department of Health Sciences,University of Florence,Florence,Italyf Institute for Maternal and Child Health,IRCCS Burlo Garofolo,Trieste,Italyg Department of Metabolic Diseases,Clinical Genetics and Diabetology,Giovanni XXIII Children's Hospital,Bari,Italyh Pediatric Clinic and Endocrinology,Regional Center for Pediatric Diabetes,IRCCS Istituto Giannina Gaslini,Genoa,Italyi Department of Pediatrics,University of Chieti,Chieti,Italyj AOU Policlinico "G. Rodolico",Catania,Italyk Department of Paediatric Haematology-Oncology,Ospedale Pediatrico Microcitemico,Cagliari,Italyl SC Onco-Ematologia Pediatrica,AOU Città della Salute e della Scienza,Turin,Italym Pediatric Oncohematology Unit,IRCCS Azienda Ospedaliero-Universitaria di Bologna,Bologna,Italyn Coordinator of the Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED),Bologna,Italy
DOI: https://doi.org/10.1080/08880018.2023.2295454
2024-01-26
Pediatric Hematology and Oncology
Abstract:Glycemic abnormalities are a frequent finding in pediatric oncological patients, both during treatment and after its discontinuation. Moreover, impaired glucose tolerance (IGT), impaired fasting glycemia (IFG) and diabetes mellitus (DM) are not rarely diagnosed in non-oncological hematological diseases. To explore the current pediatric Italian approach to the diagnosis and the management of the glycemic alterations in this clinical setting and, thus, to identify and enforce current clinical needs, we submitted an online 23-items survey to all the Italian Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) centers, and surveys were descriptively analyzed. Thirty-nine AIEOP centers were involved in the study. In 2021, among 75278 children and adolescents affected by an oncological or a hematological disease, 1.2 and 0.65% developed DM, while IGT or IFG were widespread in 2.3 and 2.8%, respectively. The main causes of DM were the use of corticosteroids in patients with cancer and the iron overload in patients with thalassemia. Venous fasting plasma glycemia was the most used tool to detect glycemic abnormalities. The performance of oral glucose tolerance test (OGTT) was extremely limited, except when IFG occurred. Despite the diagnosis of DM, ∼45% of patients with cancer and 30% of patients with one hematological disease did not receive an appropriate treatment. In the other cases, insulin was the drug of first choice. Emerging technologies for diabetes care (glucose sensors and insulin pumps) are not largely used yet. The results of our study support the standardization of the care of the glycemic abnormalities during or after onco-hematologic diseases in the pediatric age. Despite the scarce data in pediatric literature, proper guidelines are needed.
oncology,pediatrics,hematology